New ibuprofen derivatives with thiazolidine-4-one scaffold with improved pharmaco-toxicological profile

Table 3 Cell viability (%) of ibuprofen derivatives (4a-n) at 10 μg/ml

Comp.	24 h	48 h	72 h	Comp.	24 h	48 h	72 h
4a	61.36 ± 1.17	59.69 ± 1.23	57.62 ± 1.26	4 h	80.38 ± 1.39	74.95 ± 1.86	64.76 ± 1.42
4b	56.38 ± 1.50	52.01 ± 0.73	38.76 ± 0.76	4i	89.03 ± 0.66	78.43 ± 1.17	77.16 ± 1.47
4c	82.20 ± 1.24	79.39 ± 1.01	69.86 ± 1.86	4j	51.95 ± 1.42	41.04 ± 0.12	41.03 ± 0.62
4d	80.94 ± 0.88	80.74 ± 1.39	76.88 ± 1.61	4 k	92.29 ± 0.33	76.04 ± 0.95	70.97 ± 1.58
4e	84.79 ± 2.01	78.33 ± 0.95	71.19 ± 1.68	4 l	68.71 ± 1.49	62.60 ± 1.14	60.24 ± 1.77
4f	97.51 ± 2.01	90.51 ± 0.66	76.71 ± 1.68	4 m	76.89 ± 2.01	75.77 ± 1.52	61.19 ± 1.05
4 g	85.95 ± 0.89	78.06 ± 1.77	71.47 ± 1.93	4n	95.25 ± 1.74	81.10 ± 0.63	77.68 ± 1.59
Ibuprofen	92.83 ± 2.24	91.65 ± 1.68	90.46 ± 1.12	DMSO 5%	36.43 ± 1.45	14.40 ± 1.00	6.95 ± 0.38

ISSN: 2050-6511